Clinical Trial Detail

NCT ID NCT03951831
Title REGN2810 Followed by Chemoimmunotherapy for Newly Metastatic Hormone-sensitive Prostate Cancer
Recruitment Recruiting
Gender male
Phase Phase II
Variant Requirements No
Sponsors Mark Stein
Indications

prostate cancer

Therapies

Cemiplimab + Degarelix + Docetaxel + Leuprolide

Age Groups: adult senior

No variant requirements are available.